Please login to the form below

Not currently logged in
Email:
Password:

Blincyto

This page shows the latest Blincyto news and features for those working in and with pharma, biotech and healthcare.

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

The company also has an advantage in that its technology has been proven via Blincyto, the first BiTE-based therapy, approved in 2017.

Latest news

More from news
Approximately 5 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen, has had success with in-house bispecifics already, such as acute lymphoblastic leukaemia (ALL) treatment, Blincyto; the in-developme nt acute myeloid leukaemia (AML) therapy AMG 330; and multiple myeloma

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics